Collaboration for Antibody Development and Drug Improvement

Biocytogen Pharmaceuticals and Neurocrine Biosciences have signed a collaboration agreement to develop human antibodies targeting specific targets, with Biocytogen providing access to its fully human antibodies. The agreement grants Neurocrine access to selected options for development, manufacturing, and global commercialization, with potential net sales royalty payments. The antibodies were generated using Biocytogen's RenMice® platforms. TME Pharma's drug, NOX-A12, has shown improved survival rates in cancer treatment, with a median survival of 19 months and an expected improvement to 19-19.9 months.